"The Report Frontier
Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate
Pipeline, with Most Promising First-in-Class Targets Demonstrating
Potential Disease-Modifying Effects provides information on pricing,
market analysis, shares, forecast, and company profiles for key
industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz
has announced the addition of a new report to its repository, titled
“Frontier Pharma: Type
2 Diabetes Mellitus
- GPCRs And Protein Kinases Dominate Pipeline, With Most Promising
First-In-Class Targets Demonstrating Potential Disease-Modifying
Effects.” The report studies the statues of the market in its
current scenario and based on an analysis various factors that are
expected to influence the demand in the near future, it estimates the
future.
The
report observes that Type 2 diabetes mellitus (T2DM) is a
life-threatening chronic metabolic disorder, which is signified by
high glucose levels in the blood (hyperglycemia) and causes several
complications in the patients, including renal, cardiovascular, and
neurodegenerative diseases. According to the report, in the past few
decades, the prevalence of these diseases has escalated rapidly,
owing to factors such as increasing obesity cases across the world.
Noticing this rising healthcare issue, a number of players have
invested to device new drugs and as a result, the competition has
gone quite stiff in the recent past across different segments of
therapy of the market. For instance, new drugs such as dipeptidyl
peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1)
receptor agonists, and sodium-glucose cotransporter 2 (SGLT-2) have
been quite successful commercially and have now own a significant
share of the market.
However,
there still is vast population base with unmet needs for Type 2
diabetes mellitus, which is urging further investments on research
and development of first-in-class drugs across various regions. The
report finds that first-in-class products amount for a notable chunk
of the market, and identifies several T2DM pipelines that may enter
the market in the near future.
The
report not only studies the competitive landscape, it also throws
light on strong investment in first-in-class innovations and
highlights opportunities available for the investors including
biologic products, diversification of molecular targets, and the
shift in regulatory and reimbursement policies. The 88-page report
classifies treatment and management of Type 2 diabetes mellitus into
insulin-based T2DM therapies and non-insulin based T2DM therapies.
The section of the report on T2DM signaling network, disease caution
and innovation alignment focuses on the complexity of signaling
network and pathways of molecular target integration, besides
assessing the first-in-class matrix.
View
Press Release @
http://www.marketresearchreports.biz/pressrelease/3736
Some
of the prominent first-in-class target and pipeline programs
evaluated in the report include insulin receptor substrate 1 and
insulin receptor substrate 2, G-protein coupled receptor kinase, Type
2 angiotensin II receptor, islet amyloid polypeptide, nacht LRR and
PYD domains containing protein, peroxisome proliferate activated
receptor gama coactivator 1 alpha (PPARGC1A), glucagon, alpha
synuclein, and microtubule associated protein tau. The section on
strategic consolidations examines industry-wide first-in-class deals,
licensing deals, co-development deals, and first-in-class programs
that are not involved in licensing or co-development deals.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment